| 64.43 -0.03 (-0.05%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 75.41 | 1-year : | 88.08 |
| Resists | First : | 64.56 | Second : | 75.41 |
| Pivot price | 49.23  |
|||
| Supports | First : | 45.83 | Second : | 34.25 |
| MAs | MA(5) : | 64.43 |
MA(20) : | 46.65 |
| MA(100) : | 29.37 |
MA(250) : | 18.44 |
|
| MACD | MACD : | 7.6 |
Signal : | 5.2 |
| %K %D | K(14,3) : | 99.6 |
D(3) : | 99.6 |
| RSI | RSI(14): 83.4 |
|||
| 52-week | High : | 64.56 | Low : | 6.71 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ALPN ] has closed below upper band by 20.0%. Bollinger Bands are 471.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 64.51 - 64.94 | 64.94 - 65.3 |
| Low: | 63.57 - 64 | 64 - 64.36 |
| Close: | 63.8 - 64.5 | 64.5 - 65.08 |
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Wed, 17 Apr 2024
INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPN - PR Newswire
Wed, 17 Apr 2024
Alpine Immune Sciences' (ALPN) Hold Rating Reiterated at TD Cowen - Defense World
Wed, 17 Apr 2024
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Short Interest Update - Defense World
Mon, 15 Apr 2024
Alpine Immune Sciences Announces Company Presentation and Update on AACR Investor Event - The Globe and Mail
Thu, 11 Apr 2024
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today - InvestorPlace
Wed, 10 Apr 2024
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy - Morningstar
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 4.492e+007 (%) |
| Held by Institutions | 4.6 (%) |
| Shares Short | 4,430 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.367e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -54.7 % |
| Operating Margin | 5 % |
| Return on Assets (ttm) | -8.4 % |
| Return on Equity (ttm) | -12.7 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 9.82 |
| Sales Per Share | 5.07586e+007 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -79 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 13.76 |
| Dividend | 0 |
| Forward Dividend | 5.28e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|